CompletedHealthcare9 November 2026

Abeona Therapeutics Inc. acquires APT-1011 (ABO-801) assets of Ellodi Pharmaceuticals, L.P.

Verified deal facts, source-backed narrative, and the Exit Mode founder lens for SME readers preparing to sell.

Deal facts

Buyer
Abeona Therapeutics Inc.
Target
APT-1011 (ABO-801) assets of Ellodi Pharmaceuticals, L.P.
Deal value
USD 20,000,000
Announced
9 November 2026
Status
Completed
Sector
Healthcare
Country
United States
Consideration
shares, earn-out
What we know

Abeona Therapeutics Inc. bought substantially all assets related to the research, development, manufacture and commercialization of APT-1011 from Ellodi Pharmaceuticals, L.P. under an asset purchase agreement that was entered into and closed on 6 November 2026. Abeona announced the acquisition in a press release on 9 November 2026 and now calls the candidate ABO-801. This is a purchase of a product candidate, not of Ellodi as a company. APT-1011 is a once-daily orally disintegrating tablet formulation of fluticasone propionate being developed for eosinophilic esophagitis, a chronic inflammatory disease of the esophagus.

The base consideration is $20 million of Abeona common stock, with no upfront cash paid. Abeona issued 4,494,383 shares, with the number set by the 20-trading-day volume weighted average price ending on the trading day before closing. Ellodi can also receive $30 million on FDA approval of a New Drug Application for the product and up to a further $30 million on specified sales milestones. It is also eligible for tiered royalties on net sales ranging from low to mid teen percentages. The royalties run country by country until the latest of the last valid patent claim expiring, regulatory exclusivity expiring, or the seventh anniversary of first commercial sale in that country. The milestones and royalties are contingent and are not part of the $20 million.

Abeona says the candidate has been evaluated in a Phase 1/2a study of 24 patients, a Phase 2b study of 106 patients and two completed Phase 3 studies that enrolled 361 patients combined. Neither Phase 3 study met its prespecified co-primary patient-reported symptom endpoint, though both showed statistically significant improvements in several endoscopic measures. Abeona expects to start a new Phase 3 study in the second quarter of 2027 and anticipates topline results by the end of 2028, depending on study initiation and enrollment.

On 6 November 2026, the day of the asset purchase, Abeona also signed a separate securities purchase agreement for a private placement of about $30 million. It covers 6,400,000 shares at $3.75 each and pre-funded warrants for 1,600,043 shares at $3.7499 each, with Morgan Stanley as sole placement agent and closing expected on 10 November 2026. The shares issued to Ellodi are unregistered and were issued under an exemption from registration. One-third of them are released from lock-up at each of the 6-, 12- and 18-month anniversaries of closing, while 337,079 shares carry no lock-up. Ellodi also holds demand registration rights under a registration rights agreement dated 6 November 2026. The asset purchase agreement includes mutual indemnification for losses from certain breaches and other specified liabilities, and Abeona has determined that the transaction is not the acquisition of a business under Rule 11-01(d) of Regulation S-X.

The archive tags include an earn-out. Compare completion cash, deferred payments and earn-outs before treating a headline amount as proceeds. Check the underlying announcement for the actual conditions; tags are not a complete payment schedule.

Deal timeline

1 update
  1. CompletedClosed

    Abeona Therapeutics Inc. completes acquisition of Ellodi Pharmaceuticals, L.P.

    Item 1.01. Entry into a Material Definitive Agreement. Asset Purchase Agreement On November 6, 2026 (the “Closing Date”), Abeona Therapeutics Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Ellodi Pharmaceuticals, L.P., a Delaware limited partnership (“Ellodi”), pursuant to which Ellodi sold and assigned to the Company, and the Company purchased

    Source

For business owners

What would selling your own business involve?

Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.

Guides are free to read. Free tools require email access; indicative results are not professional advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

Similar deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

10 November 2026Firm intentionHealthcare

BioNTech US Inc. to acquire a Rare Pediatric Disease Priority Review Voucher from Scholar Rock Inc.

BioNTech US Inc. has agreed to buy a Rare Pediatric Disease Priority Review Voucher from Scholar Rock Inc. for $205 million in cash. Scholar Rock Inc. is a wholly owned…

Buyer
BioNTech US Inc.
Target
Rare Pediatric Disease Priority Review Voucher of Scholar Rock Inc.
Deal value
USD 205,000,000
Deal type
asset sale

Buyer history

Abeona Therapeutics Inc.

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive